Dec 262011

More than 65,000 people develop empyema each year, and 25% of them are in the hospital a month or longer. Past randomized trials and a meta-analysis showed streptokinase didn't help, but case series suggested tissue plasminogen activator might.

Rahman et al randomized 210 people to a 2 x 2 table: double-placebo, DNAse and t-PA, DNAse alone, or t-PA alone. The combination of DNAse and t-PA improved radiographic clearance of the pleural space (primary endpoint). Combination therapy also reduced the rate of surgery consultation by an absolute 8% (4% vs. 16%). Mean hospital stay was 5 days shorter in the combination therapy group (12 vs. 17 days); these were all prespecified secondary endpoints. There was no difference in mortality. N Engl J Med 2011;365:518-526.

Get our weekly email update, and explore our library of practice updates and review articles.

PulmCCM is an independent publication not affiliated with or endorsed by any organization, society or journal referenced on the website. (Terms of Use | Privacy Policy)


For empyema, tPA plus DNAse in the pleural space improved outcomes (RCT, NEJM)